

**BEFORE THE NATIONAL GREEN TRIBUNAL
SOUTHERN ZONE, CHENNAI**

**ORIGINAL APPLICATION No. 20 OF 2025 (SZ)
[Earlier, OA No. 1341 of 2024 (PB)]**

IN THE MATTER OF:

Tribunal on its own motion Suo Moto based on the news item in The Times of India dated 21.11.2024 titled "One dead 3 injured in reactor blast at pharma company in Hyderabad".

AND

Telangana State Pollution Control Board,
Through its Member Secretary,
Telangana and Ors.

..... Respondent (s)

REPORT OF THE TELANGANA POLLUTION CONTROL BOARD (R1)

RUNNING INDEX

Sl. No.	Particulars	Page Nos.
1.	Report of the Telangana Pollution Control Board (Respondent No.1) dated 25.03.2025.	1 – 4
2.	Annexure-I – Consent & Hazardous Waste Authorization Order dated 06.02.2023 issued by Respondent Board to M/s. Aurore Pharmaceuticals Private Ltd., Unit-I (formerly M/s. Mylan Laboratories Ltd., Unit-III), Phase-IV, IDA Jeedimetla, Quthubullapur (M), Medchal – Malkajgiri District.	5 – 14
3.	Annexure-II – Production details as per Consent & Hazardous Waste Authorization Order dated 06.02.2023.	15 – 22
4.	Annexure-III – M/s. Aurore Pharmaceuticals Private Ltd., Unit-I (formerly M/s. Mylan Laboratories Ltd., Unit-III), Phase-IV, IDA Jeedimetla, Quthubullapur (M), Medchal – Malkajgiri District letter dated 13.03.2025 addressed to the Respondent Board.	23 – 46
5.	Annexure-IV – Hon'ble NGT, Chennai Order dated 08.02.2025 in OA No. 20 of 2025 (SZ).	47 – 48

Place: Hyderabad

Date: 25-03-2025.



COUNSEL FOR RESPONDENT No. 1

Report of the Telangana Pollution Control Board (Respondent No.1) in OA No. 20 of 2025 (Earlier O.A No. 1341 of 2024 PB, New Delhi taken up suo motu based on the news item appeared in the Times of India dated 21.11.2024)

It is to submit that the Hon'ble NGT, Principal Bench, New Delhi has registered suo motu case based on the news item published in the Times of India dated 21.11.2024 titled "one dead 3 injured in reactor blast at pharma company in Hyderabad" which was numbered as O.A No. 1341 of 2024 (PB). The Hon'ble NGT, New Delhi has heard the matter on 28.11.2024 and passed the following order:

"This original application is registered suo motu on the basis of the news item titled "one dead 3 injured in reactor blast at pharma company in Hyderabad appearing in the "Times of India" dated 21.11.2024.

The news item relates to a flash fire triggered by a reactor blast at a pharmaceutical company in Hyderabad, resulting in the death of one man and injuries caused to three others. As per the article, the incident occurred while the four workers were repairing the reactor.

The news item does not indicate that any steps have been taken for payment of compensation to the victims of the accident. The Tribunal in M.A No. 46/2022 in Original Application No. 05/2022 In re: News item published in The Indian Express dated 07.01.2022 titled "Gujarat: At least 06 dead, 20 sick after gas leak at industrial area in Surat" in a similar case of gas leak while awarding the compensation to family members of the victims had held as under:-

"The heirs of the deceased are entitled to compensation atleast @ ₹20 lakhs in respect of each death and @ ₹10 lakhs to each of those who fell sick on principle of restitution laid down inter alia in Sarla Verma (2009) 6 SCC 121 and Uphaar (2011) 14 SCC 481....."

".....

..... Hence, we implead the TGPCB, CPCB, MoEF&CC and District Magistrate.

..... Since the matter falls within the jurisdiction of Southern Zonal Bench of the Tribunal, therefore, the OA is transferred to the Southern Zonal Bench, Chennai for appropriate further action. Let the original record of the OA be transferred to Southern Zonal Bench, Chennai.”

The Hon'ble NGT, Chennai has taken up the case on 08.02.2025 transferred from Principal Bench, New Delhi and re-numbered as O.A. No. 20 of 2025 (SZ) and directed the respondents to file their Respective Reports and posted the matter for hearing on 01.04.2025.

In this regard the following is submitted:

- 1) M/s. Aurore Pharmaceuticals Private Ltd., Unit – I (Formerly M/s Mylan Laboratories Ltd., Unit – III), Plot No. 35, 36, 38 to 40, 49 to 51, Phase-IV, IDA, Jeedimetla, Quthubullapur (M), Medchal-Malkajgiri District and is engaged in manufacture of Bulk drugs and Intermediates.
- 2) The Board issued CFO & HWA order to the industry on 06.02.2023 for manufacturing of 79 Nos bulk drugs with a condition that the industry shall manufacture maximum 7 products at a time i.e., 3 products from Group- A & 2 products each from Group-B & Group-C with a validity upto 31.12.2027. Copy of the CFO order is enclosed as **Annexure - I**.
- 3) The Production details, water consumption and wastewater generation and solid wastes generation as per CFO &HWA Order, dt: 06.02.2023 are enclosed as Annexure-II.
- 4) The Fire accident occurred at M/s. Aurore Pharmaceuticals Private Ltd., Unit – I (Formerly M/s Mylan Laboratories Ltd., Unit – III), Plot No. 35, 36, 38 to 40, 49 to 51, Phase-IV, IDA, Jeedimetla, Quthubullapur (M), Medchal-Malkajgiri District
- 5) The unit consists of 5 blocks and the Fire accident has occurred at Production block MB-IV in the reactor located in the clean room of the block.
- 6) Total 4 members were present when the accident occurred on 20.11.2024. One person died on the spot and another person succumbed to injuries while undergoing treatment and another 2 persons were injured in the accident.

- 7) The Board Officials inspected the industry on 20.11.2024 and 10.03.2025. During the inspection, it was observed that the accident took place at Production block MB-IV in the reactor located in the clean room. As per the information provided by the Industry representative, the accident occurred during the cleaning of SS reactor with Methanol solvent, the accident took place with flash fire due to the static electricity. At the time of the accident, 4 persons were present at the reactor. Due to the impact of the accident, one person died on the spot and 3 persons were injured and were shifted to hospital for treatment. The second person succumbed to injuries while undergoing treatment at hospital leading to 2 deaths.
- 8) The industry representative informed that in the reactor where accident took place, they were manufacturing Bilastine, which is a consented product in Group – C of the CFO.
- 9) During the inspection, it was observed that the said reactor was located in a clean room of production block – IV and due to the fire accident impact, the false ceiling roof and also the door glasses were broken due to the impact which indicates that it is not only a flash fire but could be a blast occurred.
- 10) The fire was brought under control by using the fire hydrant water by the industry. There was no discharge of effluents to outside the industry observed.
- 11) During the inspection, it was observed that the industry has stopped production in the production Block MB - IV.
- 12) During the inspection, no damage to the environment is observed.
- 13) At present, it is observed that the Clean Room where the accident took place in Production Block MB-IV is under renovation.
- 14) As per the information provided by the industry, 2 persons died due to the said accident and another 2 persons injured. The industry has paid compensation amount to the family of the dead after the mutual agreement by the family and also paid the hospital treatment charges for the injured persons. The details are as follows:
 - i. Compensation amount of Rs.41,00,000/- was paid to the family of Mr. B. Anil Kumar as a death benefit.
 - ii. Compensate amount of Rs.45,00,000/- was paid to the family of Mr. Majji Balaram.

Copies of the cheques and copies of the confirmation of the receipt compensation documents as given by the family of the dead as submitted by the industry are enclosed for kind information. (**Annexure – III**).

iii. Details of Hospital Treatment charges paid by the Industry:

Sl.No.	Employee Name	Designation	Hospital Charges paid (Rs.)	Treatment done at
1.	V. Srinivasa Reddy	Contact Helper	23,15,381/-	Yashoda Hospital, Secunderabad
2.	V. Gopi Chand	Employee	56,62,824/-	Appollo Hospital, DRDO, Hyderabad
3.	Majji Balaram (who died under treatment)	Contract Helper	2,48,779/-	Wellness Hospital, Hyderabad.

It is further to submit that, the Department of Factories, Medchal Malkajiri District have investigated the matter and issued notice dated 21.11.2024 to the occupier and manager of the industry and also filed a case in the Hon'ble Court of the VIII Metropolitan Magistrate Cybarabad at Medchal.

Submitted.

Date: 25.03.2025

Place: Hyderabad

R. Rajender

ENVIRONMENTAL ENGINEER
Environmental Engineer
T.G. Pollution Control Board
Regional Office, Medchal.



**CONSENT & HWA ORDER (CHANGE OF PRODUCT MIX)
 RED CATEGORY**

Consent Order No.:230523664610

Date: 06.02.2023

(Consent Order for Existing/New or altered discharge of sewage and/or trade effluents/outlet under Section 25/26 of the Water (Prevention & Control of Pollution) Act, 1974 and amendments thereof, Operation of the plant under section 21/22 of Air (Prevention & Control of Pollution) Act 1981 and amendments thereof and Authorisation / Renewal of Authorisation under Rule 6 of the Hazardous Wastes (Management, Handling & Transboundary, Movement) Rules 2016 & Amendments thereof).

CONSENT is hereby granted under section 25/26 of the Water (Prevention & Control of Pollution) Act, 1974, under section 21/22 of Air (Prevention & Control of Pollution) Act 1981 and amendments thereof, and Authorisation under the provisions of HW (MH & TM) Rules, 2016 (hereinafter referred to as 'the Acts', 'the Rules') and amendments thereof and the rules and orders made there under to **M/s. Aurore Pharmaceuticals Private Ltd., Unit – I (Formerly M/s Mylan Laboratories Ltd., Unit – III), Plot No. 35, 36, 38 to 40, 49 to 51, Phase-IV, IDA, Jeedimetla, Quthubullapur (M), Medchal-Malkajgiri District** (hereinafter referred to as 'the Applicant /Industry') and the industry is authorized to operate the industrial plant to discharge the Effluents from the outlets and the quantity of Emissions per hour from the chimneys, by operating pollution control equipment, as detailed below,

i) Out lets for discharge of Effluents:

Outlet No.	Outlet Description	Max Daily Discharge (KLD)	Point of Disposal
1	HTDS effluents Process effluent	21.1	<ul style="list-style-type: none"> Shall be transported to APL, Unit-II in SVCIE, Jeedimetla for treating in MEE & ATFD system. Condensate should be treated in ETP followed by RO.
2	Low TDS effluents Washing – 1.7 KLD, Boiler blow down – 1.1 KLD, Cooling bleed off – 1.0 KLD, Domestic -25.6 KLD	29.4	<ul style="list-style-type: none"> shall be transported to APL, Unit-II for treating in ETP followed by RO system, along with MEE & ATFD condensate. RO permeate should be reused within the premises as cooling water makeup / Boiler. RO rejects should be treated in MEE.
	Total	50.5 KLD	

ii) Emissions from chimneys:

Chimney No.	Description of Chimney
1.	Attached Briquette / coal fired Boiler of capacity 4.0TPH*
2.	Attached to Process Emissions
3.	Attached to DG set of capacity 3 x 750 KVA & 1 x 500 KVA

***The industry is permitted to use coal for 30 days / annum in case of non- availability of Briquette / coal.**

6

iii) HW Authorisation No.:230523664614Date : 06.02.2023

**HAZARDOUS WASTE AUTHORISATION
(FORM – II)
[See Rule 6 (2)]**

M/s. Aurore Pharmaceuticals Private Ltd., Unit – I (Formerly M/s Mylan Laboratories Ltd., Unit – III), Plot No. 35, 36, 38 to 40, 49 to 51, Phase-IV, IDA, Jeedimetla, Quthubullapur (M), Medchal-Malkajgiri District is hereby granted an authorization to operate a facility for collection, reception, storage, treatment, transport and disposal of Hazardous Wastes namely:

• **Hazardous wastes with disposal option:**

S. No.	Name of the Hazardous Waste	Stream	Quantity	Disposal option
1	Spent carbon	28.2 cf Schedule-I	4.839 TPM	Shall be disposed to Cement Units for Co-processing / AFR facilities for pre-processing (or) M/s. TSDF for pre-processing.
2	Process Organic residue	28.1 cf Schedule-I	10 TPM	
3	ETP sludge	34.3 cf Schedule-I	3 TPM	
4	Distillation Bottom residue	36.4 of Schedule-I	14 TPM	
5	Inorganic salts	28.1 cf Schedule-I	10.974 TPM	

• **Hazardous wastes with recycle option:**

S. No.	Name of the Hazardous Waste	Stream	Quantity	Disposal option
1	Used oil / waste lubricating oil	5.1 of Schedule –I	0.3 TPM	Shall be disposed to authorized Recyclers / Re-processors
2	Detoxified containers & container liners	33.3 of Schedule –I	100 Nos/Month	After complete detoxification, it should be disposed to the outside agencies.
3	Spent Catalyst (Solid waste) (a) Ammonium Sodium phosphate (b) Cuprous Waste	28.2 of Schedule –I	a) 15 TPM b) 4 TPM	Shall be sent back to the manufacturer for regeneration / to TSDF, Dundigal for secured land filling.
4	Glass bottles of different sizes	-	100 Nos./month	Shall be disposed to authorized Recyclers
5	E-waste	18 of Schedule –IV	1 TPA	Shall be disposed to authorized recyclers / dismantlers

This consent order is valid for the manufacture of the following products along with quantities only with a condition that the industry shall manufacture maximum 7 Products at a time i.e., 3 products from Group-A & 2 products each from Group-B & Group-C.

Sl. No.	Name of the Product	Quantity (Kg/day)	No. of Stages	Starting raw material	Quantity (Kg/day)
Group-A (Regular Products)					
1.	Levofloxacin	133.33	3	Levo ethyl ester	132.11
2.	Citalopram HBr (CSP)	150.00	5	1-Bromo-4-Flourobenzene	127.5

3.	Venlafaxine	66.67	2	4-Methoxy phenyl acetonitrile	85.62
	Group A Total	350.00 kg/day			
	Group B (Campaign Products) any 2 products				
4.	Moxifloxacin	66.67	5	Moxifloxacin acid	92.59
5.	Itraconazole	66.67	3	DTMDM	47.28
6.	Carvedilol	13.33	5	2-(2-Methoxyphenoxy) ethylamine Hydrochloride	29.7
7.	Zolpidem	11.67	3	MMPIPA	14.57
8.	Montelukast	3.33	4	Methyl-2-[3-[3-(2-(7-Chloro quinolin-2-yl)ethenyl]phenyl)-3-chloro propyl] benzoate Hydrochloride	16.41
9.	Celecoxib	133.33	2	4-Methyl Acetophenone	82.96
10.	Citalopram HBr (SRP)	10.67	6	1-Bromo-4-Fluorobenzene	18.98
11.	Emtricitabine	200.00	3	FCE	417.09
12.	Mirtazapine	8.33	2	Carboxypyridyl phenyl methyl piperazine (CPMP)	13.89
13.	Esomeprazole	10.00	4	2-Chloromethyl-4-methoxy-3,5-Dimethylpyridine Hydrochloride	20.7
14.	Modafinil	8.33	4	Benzhydrol	10.83
15.	Olanzapine	50.00	3	2-Methyl-4-amino-10Hthieno [2,3-b][1,3] benzodiazepine Hydrochloride	133.33
16.	Candesartan	50.00	4	CBBI	45.57
17.	Escitalopram	6.67	5	1-Bromo-4-Fluorobenzene	17.85
18.	Telmisartan	50.00	3	MPB	46.79
19.	Aripiprazole	16.67	4	7-Hydroxy-3,4-dihydro carbostyryl	25.0
20.	Etoricoxib	100.00	2	1-(6-Methylpyridin-3-yl)-2-(4-(methylsulfonyl)phenyl)ethanone	105.6
21.	Benazepril Hydrochloride	66.67	4	HPBE	66.67
22.	Desvenlafaxine	50.00	5	2-(4-Hydroxyphenyl)acetic acid	55.0
23.	Levothyroxine Sodium	33.33	5	L-Tyrosine	21.33
24.	Armodafinil	66.67	2	DMSA	93.33
25.	Tolvaptan	16.67	5	Methyl-2-amino-5-chloro benzoate	16.67
26.	Verapamil Hydrochloride	100.0	1	3,4-Dimethoxy phenyl-Nmethylethylamine	66.0
27.	Favipiravir	66.67	3	6-Bromo-3-hydroxypyrazine-2-carboxamide	133.0
28.	Dronedarone Hydrochloride	100.0	1	N-(2-Butyl-5-benzofuranyl) methanesulfonamide	53.0
29.	Erdosteine	100.0	3	DL-Homocysteine Thiolactone	96.0

30.	Fesoterodine Fumarate	50.0	5	3,4-Dihydro-6-(hydroxymethyl)-4-phenyl-2H-chromen-2-ol	107.14
31.	Fimasartan	33.33	4	2-(2-Butyl-1,6-dihydro-4-methyl-6-oxopyrimidin-5-yl)-N,N-dimethylacetamide	29.33
32.	Losartan Potassium	100.0	4	OTBN	60.0
33.	Mesalamine	100.0	2	2-Hydroxy-5-nitrobenzoic acid	151.33
34.	Oxcarbazepine	66.67	3	10-Methoxy-5H-dibenz[b,f]azepine-5-carbonyl chloride	160.0
35.	Pinaverium Bromide	100.0	4	2-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl) ethanol	50.0
36.	Nafamostat Mesylate	16.67	5	6-Cyano-2-naphthol	12.08
37.	Raloxifene Hydrochloride	33.33	5	1-(4-Methoxyphenyl) ethanone	23.33
38.	Tenofovir Alafenamide Hemifumarate	33.33	3	9-[(R)-2-(Phenylphosphono methoxy)propyl]adenine	68.33
39.	Clozapine	100.0	3	2,5-Dichloronitrobenzene	87.5
40.	Acyclovir	100.0	4	Guanine	115.0
41.	Levetiracetam	100.0	1	(S)-2-Aminobutanamide HCl	115.0
42.	Abacavir Sulfate	66.67	4	N-(2-Amino-4,6-dichloro-5-pyrimidinyl) formamide	83.33
43.	Citicoline Sodium	100.0	1	Citicoline	106.0
44.	Darunavir	16.67	10	L-Phenylalanine	33.33
45.	Lamivudine	100.0	3	Benzoyloxy acetaldehyde	110.0
46.	Molnupiravir	100.0	1	Uridine	106.0
47.	Vildagliptin	66.67	2	Amantadine Hydrochloride	83.33
48.	Acotiamide Hydrochloride Trihydrate	33.33	4	2,4,5-Trimethoxy	46.67
49.	Acotiamide Hydrochloride Trihydrate	66.67	4	Ethyl-3-(3-amino-4-(methyl amino)-N-(pyrid-2-yl) benzamido)propanoate	97.78
50.	2,5-Dioxopyrrolidine-1-yl(3R,3aS,6aR) tetrahydro-2H-furo [2,3-b] furan-3-yl) carbonate	100.0	2	(3aS,4S,6aR)-4-Methoxytetrahydrofuro[3,4-b]furan-2(3H)-one	82.86
51.	Ticagrelor	66.67	3	4,6-Dichloro-2-(propylthio) pyrimidin-5-amine	54.17
52.	2-(((3aR,4S,6R,6aS)-6-Amino-2,2-dimethyl tetrahydro-3aH-cyclopenta [d][1,3]dioxol-4-yl)oxy)ethanol L Tartrate	100.0	3	(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-3aH-cyclopenta[d][1,3]dioxol-4	76.47
	Group-B Total (Any 2 products)	333.33 kg/day			
	Group-C (Campaign Products) Any 2-Products				

53.	Ganciclovir	66.67	3	Guanine	57.78
54.	Marbofloxacin	4.17	7	Methyl Hydrazine Sulfate	3.96
55.	Rebamipide	100.0	1	DL-3-(1,2-Dihydro-2-oxoquinoline-4-yl) alanine Hydrochloride	82.0
56.	Salsalate	86.67	2	Salicylic acid	180.56
57.	Valganciclovir Hydrochloride	16.67	3	Ganciclovir Mono-O-acetate	19.33
58.	Eszopiclone	33.33	2	6-(5-Chloro-pyridine-2-yl)-5- hydroxy 7-oxy pyrrolo (3,4- b)pyrazine-5-one	28.0
59.	Valacyclovir Hydrochloride	15.83	2	Acyclovir	13.14
60.	Camostat Mesylate	66.7	2	4-Guanidinobenzoyl chloride	51.28
61.	Hydroxychloroquine Sulfate	33.33	2	4,7-Dichloroquinoline	19.44
62.	Dolutegravir	33.33	4	Methyl-1,4-dihydro-1-(2,2- dihydroxyethyl)-4-oxo-3- phenoxy pyridine-2- carboxylate	45.0
63.	Erythromycin Ethylsuccinate	66.67	1	Erythromycin Thiocyanate	76.67
64.	Fluphenazine Decanoate	16.67	1	Fluphenazine Dihydrochloride	15.83
65.	Tofacitinib Citrate	16.67	4	4-Chloro-7H-pyrrolo[2,3-d] pyrimidine	14.67
66.	Sibutramine Hydrochloride Monohydrate	5.0	2	1-[1-(4-Chlorophenyl)cyclo butyl)-3-methylbutylamine HCl	7.17
67.	Tadalafil	66.67	1	(1R,3R)-Methyl-1,2,3,4-tetra hydro-2-chloroacetyl-1-(3,4-methylene dioxyphenyl)-9Hpyrido[3,4-b]indol-3-carboxylate	90.0
68.	Remdesivir	16.67	3	(3aR,4R,6R,6aR)-4-(4-Amino pyrrolo[2,1-f][1,2,4] triazin-7-yl)-6-(hydroxy methyl)-2,2-dimethyl tetrahydrofuro[3,4-d][1,3] dioxole-4-carbonitrile	18.52
69.	Sitagliptin Phosphate	16.67	2	(3R)-3-[(tert-Butoxycarbonyl) amino]-4-(2,4,5- trifluorophenyl) butanoic acid	16.0
70.	Dipyridamole	43.33	1	Orotic acid	26.0
71.	Bilastine	33.33	2	1-(2-Ethoxyethyl)-2-(piperidin-4-yl)-1Hbenzo[d]imidazole	27.33
72.	Indomethacin Sodium Trihydrate	33.33	1	Indomethacin	38.67
73.	Amisulpride	33.33	1	Amisulpride Crude	34.59
74.	Bisoprolol Fumarate	33.33	5	p-Hydroxybenzaldehyde	25.0
75.	Tafamidis	33.33	3	4-Amino-3-hydroxybenzoic acid	31.11
76.	Edoxaban Tosylate	23.33	3	tert-Butyl ((1R,2S,5S)-2-amino-5-(dimethyl carbamoyl) cyclohexyl) carbamate oxalate	21.0

77.	Atazanavir Sulfate	33.33	1	tert-Butyl-2-((2S,3R)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-4-phenylbutyl)-2-(4-(pyridine-2-yl)benzyl)hydrazine carboxylate	33.33
78.	Bepotastine Besilate	33.33	3	(S)-2-(((4-Chlorophenyl)(piperidin-4-yloxy)methyl)pyridine L-Tartrate	45.33
79.	R & D Validation products	3.33	--	--	--
	Group-C Total (Any 2 products)	186.67 kg/day			
	Total Production capacity (Group-A, B & C)	870.00 kg/day			
	Maximum 7 Products at a time i.e., 3 products from Group-A & 2 products each from Group-B & Group-C.				

This order is subject to the provisions of 'the Acts' and the Rules' and amendments made thereunder and further subject to the terms and conditions incorporated in the schedule A, B and C enclosed to this order.

This consent is hereby accorded subject to the policy of Government regarding relocation of industry including modernization and expansion thereof within Outer Ring Road (ORR) from time to time.

This order of Consents and Authorization is valid for a period upto 31st December, 2027.

Sd/-
MEMBER SECRETARY

To
M/s. Aurore Pharmaceuticals Private Ltd., Unit - I
(Formerly M/s Mylan Laboratories Ltd., Unit - III),
Plot No. 35, 36, 38 to 40, 49 to 51, Phase-IV,
IDA, Jeedimetla, Quthubullapur (M),
Medchal-Malkajgiri District

///T.C.F.B.O///


SENIOR ENVIRONMENTAL ENGINEER
(Unit-I) 9/5/2026

SCHEDULE - A

1. The applicant shall make applications through online for renewal of Consent (under Water & Air Acts) and Authorisation under HWM Rules at least 120 days before the date of expiry of this order, along with prescribed fee under Water and Air Acts for obtaining Consent & HW Authorisation of the Board. The applicant can also apply for Auto Renewal of the CFO at least 30 days before the expiry of this order as per the procedure and eligibility stipulated in the Board Circular dt.19.11.2015 & 08.12.2015 (available in Board's Website: <http://tspcb.cg.gov.in/Pages/Circulars.aspx>).
2. This order is issued in line with Board's CFO & HWA order dt. 16.06.2015 & Auto Renewal CFO & HWA order dt. 10.03.2017 & CFE (change of product mix) order dt. 25.06.2022. Concealing the factual data or submission of false information/ fabricated data and failure to comply with any of the conditions mentioned in this order may result in withdrawal of this order and attract action under the provisions of relevant pollution control Acts. The industry shall comply with all other conditions of CFO & HWA order dt. 16.06.2015 & Auto Renewal CFO & HWA order dt. 10.03.2017 & CFE (change of product mix) order dt. 25.06.2022 is still applicable.
3. Any person aggrieved by an order made by the State Board under Section 25, Section 26, Section 27 of Water Act, 1974 or Section 21 of Air Act, 1981 may within thirty days from the date on which the order is communicated to him, prefer an appeal as per Rules, to such authority (hereinafter referred to as the Appellate Authority) constituted under Section 28 of the Water (Prevention and Control of Pollution) Act, 1974 and Section 31 of the Air (Prevention and Control of Pollution) Act, 1981.
4. The industry may explore the possibility of tapping the solar energy for their energy requirements.
5. The Board reserves its right to modify above conditions or stipulate any further conditions and to take action including revoke of this order in the interest of protection of public health and environment.

SCHEDULE - B

1. Total Water Consumption shall not exceed after change of product mix 132.0 KLD

S. No.	Purpose	Quantity (KLD)
1	Process & Washing	25.0
2	Cooling	30.0
3	Boiler feed	35.0
4	Domestic	32.0
5	Gardening	10.0
	Total	132.0

2. The industry shall send LTDS effluents to M/s. IDPL, Balanagar for a period of maximum 15 days in a calendar year i.e., during maintenance / break down of RO system and should not contain constituent in excess of the tolerance limits prescribed below.

Parameter	Limiting Standards
pH	5.5 – 9.0
Temperature °C	45.0
Total Dissolved Solids (Inorganic)	5,000 mg/l
Oil and Grease	20 mg/l
Phenolic Compounds (as C ₆ H ₅ OH)	5 mg/l
Ammonical Nitrogen (as N)	50 mg/l
Cyanide (as CN)	2 mg/l
Chromium Hexavalent (as Cr ⁺⁶)	2 mg/l
Chromium (total) (as Cr)	2 mg/l
Copper (as Cu)	3 mg/l
Lead (as Pb)	1 mg/l

Nickel (as Ni)	3 mg/l
Zinc (as Zn)	15 mg/l
Arsenic (as As)	0.2 mg/l
Mercury (as Hg)	0.01 mg/l
Cadmium (as Cd)	1 mg/l
Selenium (as Se)	0.05 mg/l
Fluoride (as F)	15 mg/l
Boron (as B)	2 mg/l
COD	15.000 mg/l

3. The emissions shall not contain constituents in excess of the prescribed limits mentioned below.

Chimney No	Description of Chimney	Parameter	Emission standards
1.	Attached Coal/Briquette fired Boiler of capacity 4.0TPH	SPM	115 mg/Nm ³
		SO ₂ *	600 mg/Nm ³ At 6% dry O ₂ , for solid fuel and 3% dry O ₂ for liquid fuel
		NO _x *	300 mg/Nm ³ At 6% dry O ₂ , for solid fuel and 3% dry O ₂ for liquid fuel
2.	Attached to Process Emissions	HCl	35 mg/Nm ³
3.	Attached to DG set of capacity 3 x 750 KVA & 1 x 500 KVA	SPM	115 mg/Nm ³

*As per MOEF&CC Notification No.GSR 96(E), dt. 29.01.2018 published under the Environment (Protection) Rules, 1986.

- The industry shall comply with emission limits for DG sets upto 800 KW as per the Notification G.S.R.520 (E), dated 01.07.2003 under the Environment (Protection) Amendment Rules, 2003 and G.S.R.448(E), dated 12.07.2004 under the Environment (Protection) Second Amendment Rules, 2004. In case of DG sets more than 800 KW should comply with emission limits as per the Notification G.S.R.489 (E), dated 09.07.2002 at serial no.96, under the Environment (Protection) Act, 1986.
- The industry shall comply with ambient air quality standards of PM₁₀(Particulate Matter size less than 10µm) - 100 µg/ m³; PM_{2.5}(Particulate Matter size less than 2.5 µm) - 60 µg/ m³; SO₂ - 80 µg/ m³; NO_x - 80 µg/m³, outside the factory premises at the periphery of the industry.

Standards for other parameters as mentioned in the National Ambient Air Quality Standards CPCB Notification No.B-29016/20/90/PCI-I, dated 18.11.2009

Noise Levels: Day time - (6 AM to 10 PM) - 75 dB (A)
Night time - (10 PM to 6 AM) - 70 dB (A).

- The industry has paid CFO fee Rs. 12,59,550/- upto 31.05.2026.
- The industry shall pay balance consent fee annually as per rates notified in G.O.Ms.No.22. The payment of annual consent fee shall be made at the concerned RO for every financial year (i.e., April to March) within the stipulated time period i.e., 1st quarter of every financial year (April to June) is mandatory for the industry / project, failing which, the validity of the Consent Order automatically stands cancelled and operation industry / project without valid consent attracts penal action under the provision of Water Act, Air Act & Hazardous and Other Wastes (Management & Transboundary Movement) Rules, 2016.
- The industry either paying annual fee or total fee for Consented period, shall pay the balance fee as per the revised rates as applicable from time to time.
- The industry shall maintain separate water meters for recording water consumption for process, boiler feed, cooling and domestic purposes and also maintain daily records.
- The industry shall segregate effluents into LTDS & HTDS effluents separately.

11. The industry shall collect first run of water / LTDS and same shall be treated within the premises or sent to CETP (M/s.IDPL, Balanagar) for further treatment duly following the manifest system.
12. The industry shall provide and maintain hood with extraction systems to the HTDS collection tanks and connect to the scrubbers to control the odour problem.
13. The industry shall carry out Leak Detection and Repair Study (LDAR) to access the solvent losses.
14. The industry shall maintain digital flow meters with totalisers (RS-485 communication) for recording the quantity of HTDS effluents, LTDS effluent and also maintain daily records. They shall connect the flow totaliser data to TSPCB & CPCB servers as per CPCB protocol.
15. The industry is permitted to send HTDS effluents to the MEE system of M/s. JETL, Jeedimetla for a period of maximum 15 days in a calendar year i.e. during maintenance / break down of MEE system and shall maintain records.
16. The industry shall monitor VOCs in ambient air with online VOC analyzer & connect the data to TSPCB server.
17. The industry shall maintain elevated platform with leachate/spillages collection pit to store drums containing chemicals & wastes to control spillages / discharges of chemicals / effluents on ground.
18. The industry shall maintain IP camera with PAN, TILT Zoom, 5x or above focal length, with night vision capability at effluent collection system (HTDS & LTDS) as per CPCB norms. They shall connect the data to CPCB & TSPCB server.
19. The industry shall provide and operate IP Camera with PAN, Zoom, 5x or above focal length, with night vision capability, at main gate entrance & at other gates where there is movement of effluent tankers, Solvent tankers, Chemical tankers, Hazardous Waste carrying vehicles & other material carrying vehicles. These cameras shall be connected to the website of TSPCB, with minimum backup of three months.
20. The industry shall develop greenbelt as per norms.
21. The industry submitted Bank Guarantee of Rs. 16 lakhs towards commitment to comply with Board conditions / directions with validity upto 12.07.2023. The Bank Guarantee amount will be forfeited, if the industry fails to comply with standards / conditions / directions of the Board. The industry shall renew the Bank Guarantee till further orders of the Board.
22. The industry shall maintain separate energy meters for recording energy consumption for air pollution control equipments and maintain record for daily energy consumption.
23. There should not be any spillages / discharges of chemicals / effluents on ground. The drums containing chemicals & wastes should be stored on elevated platform provided with leachate/spillages collection pit. In no case the drums should be stored on naked ground. The industry should provide dyke walls for storage tanks / areas to contain the spillages.
24. The industry should not discharge any wastewater within or outside the factory premises.
25. (a) The industry shall maintain the following records and the same shall be made available to the Board Officials during the inspection.
 - i) Quantity of Effluents generated sent to M/s JETL/ IDPL.
 - ii) Log Books for pollution control systems.
 - iii) Daily solid waste generated and disposed

(b) The industry shall submit consolidated statement of the above on monthly basis to the Concerned Regional Office.
26. As per G.O.Rt.No.286, the industry shall transport the industrial effluents and plying on the roads is allowed between 6 A.M. to 6 P.M. only.
27. The industry shall maintain concreted internal roads by cleaning regularly to avoid fugitive emissions due to vehicular movement.

28. The industry shall comply with Task Force directions issued by the Board from time to time.
29. The applicant shall submit Environment statement in Form V to the Regional office before 30th September of every year as per Rule No.14 of E(P) Rules, 1986 & amendments thereof.
30. The conditions stipulated in this order are without any prejudice to rights and contentions of this Board in any Hon'ble court of Law.

SCHEDULE - C

[see rule 6(2)]

[SPECIAL CONDITIONS OF AUTHORISATION FOR OCCUPIER OR OPERATOR HANDLING HAZARDOUS WASTES]

1. The industry shall give top priority for waste minimization and cleaner production practices.
2. The industry shall not store hazardous waste for more than 90 days as per the Hazardous and other Wastes (Management, Handling and Transboundary Movement) Rules, 2016 and amendments thereof. The industry shall maintain 6 copy manifest system for transportation of waste generated and copies of receipt of Consignee shall be submitted to the Concerned Regional office. The industry shall maintain proper records for Hazardous Wastes stated in Authorisation in FORM-3 i.e., quantity of incinerable waste, land disposal waste, recyclable waste etc., and file annual returns in Form- 4 as per Rule 20(2) of the Hazardous and other Wastes (Management, Handling & Transboundary Movement) Rules, 2016 and amendments thereof.
3. The industry shall dispose /sell the Hazardous Waste to only industries/agencies authorized by the State Pollution Control Boards. The industry shall verify the authorization of the Board given to the Party before disposing its waste to the External Party.
4. The industry shall maintain proper records for Hazardous Wastes disposal and its concurrence with authorization. In case of variation in generation, industry shall submit explanation and obtain amendment in Environmental Clearance/ CFE/CFO in this regard.
5. The industry shall store Used / Waste Oil and Used Lead Acid Batteries in a secured way in their premises till its disposal. Waste oils shall be disposed to the authorized Reprocessors/ Recyclers and Used Lead Acid Batteries shall be disposed to the manufacturers / dealers on buyback basis. The industry shall take necessary practical steps for prevention of oil spillages and carryover of oil from the premises. The industry shall check the Certificate/ Authorisation/order of MoEF issued to the Re-user/Recycle units while disposing the waste oil.
6. The industry shall dispose of e-waste to the authorised recyclers only.
7. The industry shall maintain good housekeeping.
8. The industry shall submit the condition wise compliance report of the conditions stipulated in Schedule B & C of this Order on half yearly basis to Board Office, Hyderabad and concerned Regional Office.

Sd/-
MEMBER SECRETARY

To
M/s. Aurore Pharmaceuticals Private Ltd., Unit – I
(Formerly M/s Mylan Laboratories Ltd., Unit – III),
Plot No. 35, 36, 38 to 40, 49 to 51, Phase-IV,
IDA, Jeedimetla, Quthubullapur (M),
Medchal-Malkajgiri District.

///T.C.F.B.O///


SENIOR ENVIRONMENTAL ENGINEER
(Unit-I) 9/2/2023

Production details as per CFO &HWA Order, dt: 06.02.2023

Sl. No	Name of the Product Group A	Total Quantity (Kg/day)	No. of Stages	Starting raw material	(Kg/day)
1.	Levofloxacin	133.33	3	Levo ethyl ester	132.11
2.	Citalopram HBr (CSP)	150.00	5	1-Bromo-4-Flourobenzene	127.5
3.	Venlafaxine	66.67	2	4-Methoxy phenyl acetonitrile	85.62
	Group A Total	350.00			

Group-B

4.	Moxifloxacin	66.67	5	Moxifloxacin acid	92.59
5.	Itraconazole	66.67	3	DTMDM	47.28
6.	Carvedilol	13.33	5	2-(2-Methoxyphenoxy) ethylamine Hydrochloride	29.7
7.	Zolpidem	11.67	3	MMPIPA	14.57
8.	Montelukast	3.33	4	Methyl-2-[3-[3-(2-(7-Chloro quinolin-2-yl)ethenyl]phenyl] - 3-chloro propyl] benzoate Hydrochloride	16.41
9.	Celecoxib	133.33	2	4-Methyl Acetophenone	82.96
10.	Citalopram HBr (SRP)	10.67	6	1-Bromo-4-Flourobenzene	18.98
11.	Emtricitabine	200.00	3	FCE	417.09
12.	Mirtazapine	8.33	2	Carboxypyridyl phenyl methyl piperazine (CPMP)	13.89
13.	Esomeprazole	10.00	4	2-Chloromethyl-4-methoxy3,5-Dimethylpyridine Hydrochloride	20.7
14.	Modafinil	8.33	4	Benzhydrol	10.83
15.	Olanzapine	50.00	3	2-Methyl-4-amino-10Hthieno [2,3-b][1,3] benzodiazepine Hydrochloride	133.33

16.	Candesartan	50.00	4	CBBI	45.57
17.	Escitalopram	6.67	5	1-Bromo-4-Flourobenezene	17.85
18.	Telmisartan	50.00	3	MPB	46.79
19.	Aripiprazole	16.67	4	7-Hydroxy-3,4-dihydro carbostyryl	25.0
20.	Etoricoxib	100.00	2	1-(6-Methylpyridin-3-yl)-2-(4-(methylsulfonyl)phenyl)ethan one	105.6
21.	Benazepril Hydrochloride	66.67	4	HPBE	66.67
22.	Desvenlafaxine	50.00	5	2-(4-Hydroxyphenyl)acetic acid	55.0
23.	Levothyroxine Sodium	33.33	5	L-Tyrosine	21.33
24.	Armodafinil	66.67	2	DMSA	93.33
25.	Tolvaptan	16.67	5	Methyl-2-amino-5-chloro benzoate	16.67
26.	Verapamil Hydrochloride	100.0	1	3,4-Dimethoxy phenyl-Nmethylethylamine	66.0
27.	Favipiravir	66.67	3	6-Bromo-3-hydroxypyrazine2-carboxamide	133.0
28.	Dronedarone Hydrochloride	100.0	1	N-(2-Butyl-5-benzofuranyl) methanesulfonamide	53.0
29.	Erdosteine	100.0	3	DL-HomocysteineThiolactone	96.0
30.	FesoterodineFumarate	50.0	5	3,4-Dihydro-6-(hydroxymethyl)-4-phenyl2H-chromen-2-ol	107.14
31.	Fimasartan	33.33	4	2-(2-Butyl-1,6-dihydro-4-methyl-6-oxopyrimidin-5yl)-N,N-dimethylacetamide	29.33

32.	Losartan Potassium	100.0	4	OTBN	60.0
33.	Mesalamine	100.0	2	2-Hydroxy-5-nitrobenzoic acid	151.33
34.	Oxcarbazepine	66.67	3	10-Methoxy-5H-dibenz[b,f]azepine-5-carbonyl chloride	160.0
35.	Pinaverium Bromide	100.0	4	2-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl) ethanol	50.0
36.	NafamostatMesylate	16.67	5	6-Cyano-2-naphthol	12.08
37.	Raloxifene Hydrochloride	33.33	5	1-(4-Methoxyphenyl) ethanone	23.33
38.	TenofovirAlafenamideHemifumarate	33.33	3	9-[(R)-2-(Phenylphosphonomethoxy)propyl] adenine	68.33
39.	Clozapine	100.0	3	2,5-Dichloronitrobenzene	87.5
40.	Acyclovir	100.0	4	Guanine	115.0
41.	Levetiracetam	100.0	1	(S)-2-Aminobutanamide HCl	115.0
42.	Abacavir Sulfate	66.67	4	N-(2-Amino-4,6-dichloro-5-pyrimidinyl) formamide	83.33
43.	Citicoline Sodium	100.0	1	Citicoline	106.0
44.	Darunavir	16.67	10	L-Phenylalanine	33.33
45.	Lamivudine	100.0	3	Benzoyloxy acetaldehyde	110.0
46.	Molnupiravir	100.0	1	Uridine	106.0
47.	Vildagliptin	66.67	2	Amantadine Hydrochloride	83.33
48.	Acotiamide Hydrochloride Trihydrate	33.33	4	2,4,5-Trimethoxy	46.67
49.	Acotiamide Hydrochloride Trihydrate	66.67	4	Ethyl-3-(3-amino-4-(methyl amino)-N-(pyrid-2-yl) benzamido)propionate	97.78

(18)

50.	2,5-Dioxopyrrolidine1-yl(3R,3aS,6aR) tetrahydro-2H-furo [2,3-b] furan3-yl) carbonate	100.0	2	(3aS,4S,6aR)-4-Methoxytetrahydr ofuro[3,4-b]furan2(3H)-one	82.86
51.	Ticagrelor	66.67	3	4,6-Dichloro-2-(propylthio) pyrimidin-5-amine	54.17
52.	2-(3aR,4S,6R,6aS)-6-Amino-2,2-dimethyl tetrahydro-3aH-cyclo penta [d][1,3]dioxol4-yl)oxy)ethanol LTartrate	100.0	3	(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-3aHcyclopenta[d][1,3]dioxol-4	76.47
Group-B Total		333.33			
Group - C					
53.	Ganciclovir	66.67	3	Guanine	57.78
54.	Marbofloxacin	4.17	7	Methyl Hydrazine Sulfate	3.96
55.	Rebamipide	100.0	1	DL-3-(1,2-Dihydro-2-oxoquinoline-4-yl) alanine Hydrochloride	82.0
56.	Salsalate	86.67	2	Salicylic acid	180.56
57.	Valganciclovir Hydrochloride	16.67	3	Ganciclovir Mono-O-acetate	19.33
58.	Eszopiclone	33.33	2	6-(5-Chloro-pyridine-2-yl)-5-hydroxy 7-oxy pyrrolo (3,4-b)pyrazine-5-one	28.0
59.	Valacyclovir Hydrochloride	15.83	2	Acyclovir	13.14
60.	CamostatMesylate	66.7	2	4-Guanidinobenzoy l chloride	51.28
61.	Hydroxychloroquine Sulfate	33.33	2	4,7-Dichloroquinoline	19.44
62.	Dolutegravir	33.33	4	Methyl-1,4-dihydro-1-(2,2-dihydroxyethyl)-4-oxo-3-phenoxy pyridine-2- carboxylate	45.0
63.	Erythromycin Ethylsuccinate	66.67	1	Erythromycin Thiocyanate	76.67

64.	FluphenazineDecanoate	16.67	1	FluphenazineDihydrochloride	15.83
65.	Tofacitinib Citrate	16.67	4	4-Chloro-7H-pyrrolo[2,3-d]pyrimidine	14.67
66.	Sibutramine Hydrochloride Monohydrate	5.0	2	1-[1-(4-Chlorophenyl)cyclo butyl]-3-methylbutylamine HCl	7.17
67.	Tadalafil	66.67	1	(1R,3R)-Methyl-1,2,3,4-tetrahydro-2-chloroacetyl-1-(3,4- methylene dioxyphenyl)-9Hpyrido[3,4-b]indol-3-carboxylate	90.0
68.	Remdesivir	16.67	3	(3aR,4R,6R,6aR)-4-(4- Amino pyrrolo[2,1-f][1,2,4] triazin-7-yl)-6-(hydroxy methyl)-2,2-dimethyl tetrahydrofuro[3,4-d][1,3] dioxole-4-carbonitrile	18.52
69.	Sitagliptin Phosphate	16.67	2	(3R)-3-[(tert-Butoxycarbonyl) amino]-4-(2,4,5-trifluorophenyl) butanoic acid	16.0
70.	Dipyridamole	43.33	1	Orotic acid	26.0
71.	Bilastine	33.33	2	1-(2-Ethoxyethyl)-2- (piperidin-4-yl)-1Hbenzo[d]imida zole	27.33
72.	Indomethacin Sodium Trihydrate	33.33	1	Indomethacin	38.67
73.	Amisulpride	33.33	1	Amisulpride Crude	34.59
74.	BisoprololFumarate	33.33	5	p-Hydroxybenzylde hyde	25.0
75.	Tafamidis	33.33	3	4-Amino-3-hydroxybenzoic acid	31.11
76.	EdoxabanTosylate	23.33	3	tert-Butyl ((1R,2S,5S)-2-amino-5-	21.0

				(dimethyl carbamoyl) cyclohexyl) carbamate oxalate	
77.	Atazanavir Sulfate	33.33	1	tert-Butyl-2-((2S,3R)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-4-phenylbutyl)-2-(4-(pyridine-2-yl)benzyl)hydrazine carboxylate	33.33
78.	Bepotastine Besilate	33.33	3	(S)-2-(((4-Chlorophenyl)(piperidin-4-yloxy)methyl)pyridine L-Tartrate	45.33
79.	R & D Validation products	3.33	--	--	--
	Group-C Total	186.67 kg/day			
Total Production capacity (Group-A, B & C)		870.00 kg/day	Maximum 7 Products at a time i.e., 3 products from Group-A & 2 products each from Group-B & Group-C.		

2) i) Water Consumption		
S.No	Purpose	Quantity (KLD)
1	Process & Washing	25.0
2	Cooling	30.0
3	Boiler feed	35.0
4	Domestic	32.0
5	Gardening	10.0
	Total	132.0

ii) Waste Water Generation in KLD	:	
-----------------------------------	---	--

Outlet Description	Max Daily Discharge in KLD	Point of Disposal
High TDS effluents:	21.1	• Should be transported to APL, Unit-II in

Process effluents		SVCIE, Jeedimetla for treating in MEE & ATFD system. • Condensate should be treated in ETP followed by RO.
Low TDS effluents Washing – 1.7 KLD, Boiler blow down – 1.1 KLD, Cooling bleed off – 1.0 KLD, Domestic -25.6 KLD	29.4	• Shall be transported to APL, Unit-II for treating in ETP followed by RO system, along with MEE & ATFD condensate. • RO permeate should be reused within the premises as cooling water makeup / Boiler. • RO rejects should be treated in MEE.

3) Air Emissions:

S. No	Source of Pollution	Control equipment provided	Stack height in Mts – above GL
1.	Oil fired Boiler – 1 x 4.0 TPH	MDC followed by bag filter.	30 mtrs
2.	Process emissions (HCl)	Provided 4 Nos. of double stage scrubbers for Process and 1 No. double stage for HTDS storage tank	10 mtrs
3.	DG set – 3 x 750 KVA	Acoustic Enclosure	7.5 m each above the ground level
4	DG set – 1 x 500 KVA	Acoustic enclosure	7.5m each above the ground level

4) Hazardous Wastes:-

Sl. No.	Name of the Hazardous Waste with disposal option	Stream	Qty of Haz Waste	Disposal Method
---------	--	--------	------------------	-----------------

With Disposal Option:

1	Spent carbon	28.2 of Sch-I	4.839 TPM	Shall be sent to authorized Cement Industries for co-processing / AFRF / TSDF, Dundigal.
2	Process Organic residue	28.1 of Sch-I	10 TPM	
3	Distillation Bottom residue	36.4 of Sch-I	14 TPM	
4	Inorganic salts	28.1 of Sch-I	10.974 TPM	
5	ETP Sludge	34.3 of Sch-I	3 TPM	

With Recycling option:

1	Containers & container liners of Hazardous waste & Hazardous chemicals	33.3of Sch-1	100 Nos/Month	After complete detoxification, should be disposed to outside agencies.
---	--	--------------	---------------	--

2	Waste/ Used oils from DG sets	5.1 of Sch-1	0.3 TPM	Authorized re-processors/ recyclers
3	Spent Catalyst (Solid waste) (a) Ammonium Sodium phosphate (b) Cuprous Waste	28.2 of Sch-I	15 TPM 4 TPM	Shall be sent back to the manufacturer for regeneration / to TSDF, Dundigal for secured land filling.
4	Glass bottles of different sizes	--	100 Nos./month	Authorized recyclers
5	Electrical & Electronic waste (E-waste)	18 of Sch-IV	1 TPA	Authorized dismantlers / recyclers



Aurore Pharmaceuticals Private Limited

Corporate Office : Plot # 68,69, 2nd Floor, Jubilee Heights,
Beside Shilparamam, Madhapur, Hyderabad, T.S. - 500081.
Ph: +91-40-23113211 Fax: 040-23110044
E-mail : info@auorels.com | Web : www.auorels.com
CIN : U24239TG2017PTC117032

13th Mar 2025

To
The Environmental Engineer,
Telangana State Pollution Control Board,
Regional Office-II, Uma nagar,
Begumpet, Medchal & Malkagiri (D) Hyderabad.



AEE-1
RS
13/3

Subject: Submission information with respect to accident that has happened on
20.11.2024,

Dear sir

As per your advice and following your recent inspection on 10.03.2025, I am submitting the requested details of the recent accident on 20.11.2024, including the Inspector of Factories' notice and its related documents, in relation to the suo-motu case filed against this matter. Along with this, I am providing the accident details, treatment & compensation, and case details for your kind perusal.

Thank you,

For Aurore Pharmaceuticals Pvt Ltd, Unit-I




Dr. Ravi Sankara Reddy. S
Director
Ph no: 9666634608

Encl: Enclosed Attachments.

OFFICE OF THE DY. CHIEF INSPECTOR OF FACTORIES, MEDCHAL MALKAJGIRI - I

I.O. No. A/62803/2024

Dated: 21.11.2024

INSPECTION ORDER OR NOTICE


FACTORIES ACT, 1948 AND T. S. FACTORIES RULES, 1950
AND THE GOVERNMENT NOTIFICATION ISSUED THEREON

Sir,

Upon a recent inspection of your factory on 20.11.2024 at 02:15 P.M. and on 21-11-2024 at 11.00 A.M. by me it was found to the extent indicated below that certain provisions of the Act and Rules were not being carried out.

The Orders below are issued or repeated from previous orders without prejudice to any action that this Office may take non-compliance with the provisions of the Act and Rules made there under.

Yours faithfully


(M. Manohar Reddy) 21/11/24
Deputy Chief Inspector of Factories
Medchal Malkajgiri - I

To
Sri S.Ravi Sankar Reddy
S/o Sri S.C.M.Reddy
Age : 47 Years, Occupier
Sri C.Jayapal
S/o Late Sri Chandrasekharan Pillai
Age : 58 years, Manager
M/s. Aurore Pharmaceuticals Private Limited - Unit I,
Phase-IV, Jeedimetla, Medchal Malkajgiri

25



O/C

Aurore Pharmaceuticals Private Limited

Corporate Office: Plot # 68,69, 2nd Floor, Jubilee Heights, Beside Shilparamam, Madhapur, Hyderabad, T.S. - 500081.
Ph: +91-40-23113211 Fax: 040-23110044
E-mail: info@auorels.com | Web: www.auorels.com
CIN: U24239TG2017PTC117032

APPL/CHS/SFT/IF/2024-25/Nov:
25th November 2024



To,
The Dy. Chief Inspector of Factories,
Medchal Malkajgiri - I
D.No. 10-1-200, A.C. Guards
MahaVeer Marg
Hyderabad - 500 004.

Dear Sir,

Sub: Factories Act, 1948 and Telangana State Factories Rules, 1950 - Non-Compliance of M/s. Aurore Pharmaceuticals Private Limited - Unit I, Phase IV, Jeedimetla, Medchal Malkajgiri District - Show Cause Notice issued - Our Submission request - Reg.

Ref: i) Show Cause Notice No. A/206/2024, dated: 21.11.2024,
ii) Inspection Order or Notice I.O. No.A/62803/2024 dated 21.11.2024

We refer to the Show Cause Notice issued against M/s. Aurore Pharmaceuticals Private Limited -Unit I, Phase IV, Jeedimetla, Medchal Malkajgiri District, in relation to non-compliance with the provisions of The Factories Act 1948 and the Telangana State Factories Rules, 1950.

We are here submitting the point wise complains status along with the annexure for your kind consideration and perusal.

S. No	Description	Our Submission
Section 87 and Rule 95 Sch XV Part II Para (5) (9) Part III Para (2) Read with Section 41 Rule 61 N Read with Rule 61 F (3):		
1	Failed to ensure to usage of wrist bands by the workers engaged for cleaning the reactor.	<p>A system was in place for workers to wear wrist bands to discharge any static electricity during the cleaning process. However, on the occasion in question, workers did not use the wrist bands as required because they were in a hurry to complete their work and take their tea break, which is scheduled from 10:00 AM to 10:30 AM for A Shift personnel.</p> <p>A list of personal protective equipment (PPE) provided in the clean room is enclosed as Annexure - I for your review.</p> <p>The safety procedure/checklist for cleaning the reactor clearly mandates the use of wrist bands and Safety shoes to discharge static electricity generated during the cleaning process. This procedure has been communicated to the workers during safety training. A photocopy of the safety procedure for cleaning activities is enclosed as Annexure - II for your reference.</p> <p>The training records for employees are enclosed as Annexure - III for your review. These records confirm that the employees involved were trained in the correct safety practices, and their training</p>



Factory: Unit - I, Plot No: 35,36,38,39,40,49 to 51, Phase IV, IDA Jeedimetla, Hyderabad - 500 055, Telangana, India.

Tel: +91-40-68150333 23007777 23005555 23002025 Fax: +91-40-23000677

		<p>records are further enclosed as Annexure - IV for reference.</p> <p>Precautions Taken After the Incident:</p> <p>i) Reinforced Usage of Wrist Bands:</p> <ul style="list-style-type: none"> The importance of using wrist bands has been reinforced through visual reminders and continuous monitoring to ensure compliance with safety protocols. Daily safety rounds will be conducted with a cross-functional team or safety committee members to identify any gaps or areas for improvement. Strengthening the safety team and increasing the team size to ensure close monitoring of safety practices being followed by the personnel and to be present for the critical activities. Disciplinary action will be initiated on the personnel who deviates any of the safety practices and to bring in the culture of following safety practices. The existing checklist will be strengthened and strictly enforced, with no deviations allowed by production clean room operation personnels. <p>ii) Refresher Training:</p> <ul style="list-style-type: none"> Refresher training sessions have been conducted and will continue for both regular and contract employees. These sessions emphasize the importance of using wrist bands and adhering to static electricity prevention measures during cleaning operations. A photocopy of the most recent training conducted is enclosed as Annexure - V for your review. <p>iii) Behaviour-Based Safety (BBS) Training:</p> <ul style="list-style-type: none"> Behaviour-Based Safety (BBS) training programs will be initiated for all employees to reinforce positive behaviours and ensure improved workplace safety. An inquiry is currently in progress, and the BBS program will be initiated within a week.
2	<p>Failed to provide earthing to SS mug and earth rod to HDPE carboy while the reactor</p>	<p>There is a system in place to ensure that earth rods are worn by workers to discharge static electricity during cleaning activities. However, in this case, the workers did not use the earthing system as required because they were in a rush to complete their tasks and take the tea break, which is scheduled from 10:00 AM to 10:30 AM for A Shift personnel.</p> <p>A list of personal protective equipment (PPE) provided in the clean room is enclosed as Annexure - I for your review.</p> <p>Photograph of the Earth Rod and Earth Clips: Please find enclosed photographs of the earth rod and earth clips used for earthing as Annexure - VI.</p> <p>The safety procedure clearly states that all metallic containers (such as SS mugs) and non-conductive containers (such as HDPE carboys) used during reactor cleaning must be properly earthed with the help of earth clips and earth rods, which are provided in each clean room. This procedure has been communicated to the workers during safety training. A photocopy of the safety procedure for cleaning activities is enclosed as Annexure - II for your reference.</p>



		<p>The training records for employees are enclosed as Annexure - III for your review. The employees involved were trained in these procedures, and their training records are also enclosed as Annexure - IV for your reference.</p> <p>Precautions Taken After the Incident:</p> <p>i) Improved Equipment Usage:</p> <ul style="list-style-type: none"> • SS bins will be used in place of HDPE carboys during the cleaning process to ensure better static discharge. A typical photograph is enclosed as Annexure - VII for your reference. • The existing checklist will be strengthened and strictly enforced, with no deviations allowed by production clean room operation personnels. <p>ii) Reinforced Earthing Procedures:</p> <ul style="list-style-type: none"> • The use of earth clips and earth rods has been reinforced through visual reminders and continuous monitoring to ensure compliance with the safety protocols. • Daily safety rounds with the cross-functional team and safety committee members will be conducted to identify any gaps and ensure continuous improvements. <p>iii) Refresher Training:</p> <ul style="list-style-type: none"> • Refresher training sessions will continue to be conducted for both regular and contract employees, to emphasize the importance of using earthing equipment (earth clips, earth rods) and adhering to static electricity prevention measures during cleaning operations. • A photocopy of the most recent training conducted is enclosed as Annexure - V for your review. <p>iv) Behaviour-Based Safety (BBS) Training:</p> <ul style="list-style-type: none"> • Behaviour-Based Safety (BBS) training programs are initiated for all employees to reinforce positive behaviours and improve workplace safety. • An inquiry is currently in progress, and the BBS program will be initiated within a week.
<p>3</p>	<p>Failed to prevent accumulation of solvent vapours & static charge while cleaning the reactors with methanol solvent.</p>	<p>An Air Handling Unit (AHU) system is in place in the clean rooms to ensure proper ventilation. This system is designed with excess ventilation capacity to effectively remove any additional vapors or fumes generated during the cleaning process.</p> <p>A preventive maintenance system is also in place for the proper upkeep of the AHUs. The record for the maintenance of the AHU is enclosed as Annexure - VIII for your review.</p> <p>The accumulation of solvent vapors and static charge may have occurred due to the rapid handling and splashing of methanol (a volatile organic solvent). When workers hurriedly moved from one mug to another during the cleaning, this led to an accumulation of solvent vapors. This occurred during the rush to complete the work and take the scheduled tea break from 10:00 AM to 10:30 AM for A Shift personnel.</p> <p>Precautions Taken After the Incident:</p> <p>i) Lower Explosive Limit (LEL) Meter with Hooter:</p>

I.R.




		<ul style="list-style-type: none"> • LEL meters have been installed in the clean room to monitor solvent vapor accumulation. In addition, a hooter will be installed to provide an early warning of solvent vapor levels, well before they reach the Lower Explosive Limit (LEL). This system ensures prompt detection and helps maintain safety in the clean room environment. A photograph of the installed meter is enclosed as Annexure - IX for your review. • The flash of solvents into the open reactor will be immediately discontinued. Going forward, solvents will be charged only through designated, fixed lines to ensure safety and control. <p>Additionally, training will be provided to all workers to raise awareness of the hazards associated with fast splashing and handling of methanol. This topic will be included in the safety training sessions. A photocopy of the safety training content is enclosed as Annexure - X for your reference.</p> <p>ii) Refresher Training:</p> <ul style="list-style-type: none"> • Refresher training sessions will continue to be conducted for both regular and contract employees, emphasizing the importance of safety measures, including proper methanol handling, and adherence to static electricity prevention practices. • A photocopy of the training conducted is enclosed as Annexure - V for your review. <p>iv) Behaviour-Based Safety (BBS) Training:</p> <ul style="list-style-type: none"> • Behaviour-Based Safety (BBS) programs are initiated for all employees to reinforce positive safety behaviours and improve overall workplace safety. • An inquiry is currently in progress, and the BBS program will be initiated within a week.
4	<p>Failed to provide and ensure the usage of heat-resistant face shields, heat resistant suits & hand gloves by the workers while cleaning the reactors with methanol solvent.</p>	<p>Heat-resistant face shields, heat-resistant suits, and hand gloves have been provided in the required quantities in each block and the clean room. To ensure the safety of workers during the cleaning operations.</p> <p>A list of personal protective equipment (PPE) provided in both the block and the clean room is enclosed as Annexure - I for your reference.</p> <p>The usage of PPE has been clearly communicated to the workers during safety training sessions, pep talks, and via posters.</p> <p>The training records of employees are enclosed as Annexure - III for your review. The employees involved in the cleaning activities were trained, and their individual training records are enclosed as Annexure - IV for your reference.</p> <p>A photograph of the posters displaying PPE usage guidelines is enclosed as Annexure - XI for your kind consideration.</p> <p>Precautions Taken After the Incident:</p> <p>i) Refresher Training:</p> <ul style="list-style-type: none"> • Refresher training sessions are being and will continue to be



		<p>conducted for both regular and contract employees to emphasize the importance of using heat-resistant face shields, suits, and gloves during cleaning operations.</p> <ul style="list-style-type: none"> A photocopy of the most recent training conducted is enclosed as Annexure - XII for your review. <p>ii) Regular PPE Audits:</p> <ul style="list-style-type: none"> A regular audit system has been established to verify the proper usage and condition of PPE. Daily safety rounds with a cross-functional team and safety committee members will be conducted to identify any gaps and ensure continuous improvements. <p>iii) Provision of Air-Supplied Fire-Retardant Suits:</p> <ul style="list-style-type: none"> All fire-retardant suits will be provided with an air-supply system to ensure safe operation. <p>iv) Behaviour-Based Safety (BBS) Training:</p> <ul style="list-style-type: none"> Behaviour-Based Safety (BBS) programs are initiated for all employees to reinforce positive behaviors and improve workplace safety. An inquiry is in progress, and the BBS program will be initiated within a week.
5	<p>Allowed the persons not connected with the cleaning operation of reactor inside the clean room</p>	<p>Persons who were not part of the cleaning operation were allowed inside the clean room. These individuals entered to call those persons working in the clean room to join them for the tea break, which typically occurs between 10:00 AM and 10:30 AM for A Shift workers.</p> <p>Precautions Taken After the Incident:</p> <p>i) Safety Training and Awareness:</p> <ul style="list-style-type: none"> The lessons learned from this incident are permanently included in the safety training material. Refresher training sessions have been conducted for both regular and contract employees to raise awareness of the issue. A photocopy of the training conducted is enclosed as Annexure -XIII for your review. <p>ii) Access Control Measures:</p> <ul style="list-style-type: none"> The existing access control facility will be strengthened to prevent unauthorized personnel from entering the clean room (pharma area) during cleaning, maintenance and operations. <p>iii) Behaviour-Based Safety (BBS) Programs:</p> <ul style="list-style-type: none"> Behaviour-based safety (BBS) training programs will be initiated for all employees to promote positive safety behaviours and ensure a safer work environment. An inquiry is currently in progress and the BBS program will be launched within a week.

In response to the recent incident and as part of our commitment for improving safety, we have initiated a series of corrective and preventive actions (CAPA) to address the identified issues and ensure the safe operation of our facilities. These measures include:

- Strict enforcement of Personal Protective Equipment (PPE) usage.
- Regular refresher training on safety procedures conducted by block incharges and shift incharges.
- Enhanced supervision and access control during reactor cleaning operations.



- Replacing plastic carboys with stainless steel (SS) cans to improve safety and prevent static accumulation.
- Use of spray balls for reactor cleaning to minimize human/person intervention and potential risks.
- Provision of Lower Explosive Limit (LEL) meters with hooters for early detection of solvent vapors.
- Making safety a direct responsibility of line managers to ensure constant focus on safety procedures/protocols.
- Regular safety inspections conducted by a cross-functional team, including at least one safety committee member, to identify and address any gaps.
- Discontinued the flash of solvents into the open reactor immediately. Going forward, solvents will be charged only through designated, fixed lines to ensure safety and control.
- Additionally, we have engaged a safety expert consultant to thoroughly review all our existing systems to identify potential hazards and prevent future incidents. Enclosed the work order copy as annexure-XV for your reference.

Compensation Details for the Deceased Worker's Family:

In the unfortunate event of a fatality that occurred on 20th November 2024, we extend our deepest condolences to the family of the deceased worker. In line with our commitment to support the family and fulfil our responsibilities, the following compensation package has been offered:

1. Death Benefit:

- A lump sum compensation of Rs. 41,00,000 (Rs Forty-one lakhs) has been provided to the family of Mr. B. Anil Kumar (Aadhar No: 860953056959) (contract employee), S/o. Mr. B. Anathagiri as a death benefit.
- A lump sum compensation of Rs. 45,00,000 (Rs Forty-five lakhs) has been provided to the family of Mr. Majji Balaram (Aadhar No: 462899639772) (contract employee), S/o. late Mr. M. Thirupathi Naidu, as a death benefit.
- The details are enclosed as Annexure-XIV for your reference.

2. Funeral Expenses:

- The company has covered all funeral expenses, including transportation, burial/cremation costs, and any related expenses. A sum of Rs. 1,00,000 (Rs One lakh) for each individual has been provided in cash, as per the family's requirements.

3. Medical Bills:

- All medical expenses incurred during the treatment period, if applicable, will be reimbursed in full to the family.

4. Provident Fund:

- The deceased's gratuity (if applicable) and provident fund balance will be provided to the family as per applicable laws and company policy.

5. Pension Benefits (from ESI):

- We will follow up with the Employees' State Insurance Corporation (ESIC) to process the pension application at the earliest.

We would like to assure you that all necessary safety measures have been fully implemented to safe operations at our facility. As such, we kindly request that no further action be taken against us.

We trust that these actions demonstrate our commitment to maintaining a safe working environment and fulfilling our responsibilities, enabling the smooth and uninterrupted operation of the factory.

Thanking you,

Yours faithfully,

For M/s. Aurore Pharmaceuticals Private Limited - Unit I,


S. Ravi Sankar Reddy
(Occupier)




C. Jayapal
(Manager)

IN THE COURT OF THE VIII METROPOLITAN MAGISTRATE CYBERABAD, AT
MEDCHAL

C.C. NO. _____

Between:-

State of Telangana Represented by
Inspector of Factories,
Medchal-Malkajgiri-III.

... Complainant

AND

1. Sri S. Ravi Shankar Reddy,

S/o Sri S.C.M. Reddy, Age: 47 Years (*Occupier*)

... Accused (A1)

2. Sri C. Jayapal,

S/o Late Sri Chandrasekharan Pillai, Age: 58 years (*Manager*)

... Accused (A2)

AURORE PHARMACEUTICALS PRIVATR LIMITED, Unit-I

Plot No. 35,38 to 40 & 49 to 51,

Phase-IV, Jeedimetla (V), Qutubullapur (M),

Medchal-Malkajgiri District.

◆◆◆

MAY IT PLEASE YOUR HONOUR

The following papers / enclosures connected with this prosecution case are filed:-

Sl.No.	Particulars of Papers filed with Court	No. of Pages
1	Charge Sheets (in Triplicate)	03
2	SCN No.A/ 206/2024, dt.21-15-2024 of the Dy. Chief Inspector of factories, Medchal-Malkajgiri-I (in Triplicate)	03
3	Inspection Order No. A/62803/2024, Dated: 21-11-2024 of the Dy. Chief Inspector of factories, Medchal-Malkajgiri-I. (in Triplicate)	03
4	Memo No. B1/4774/2024, Dated: 06-01-2025, of the Director of Factories, Telangana, Hyderabad. (in Triplicate)	03
5	Summons for Signature (in duplicate)	02



[Handwritten Signature]
INSPECTOR OF FACTORIES
Medchal-Malkajgiri-III Circle
Medchal-Malkajgiri-District

33



తెలంగాణ తెలంగాణ TELANGANA

S. Sree Chremi
BG 419777

Tran Id: 241120200718389366
Date: 20 NOV 2024, 08:11 PM
Purchased By:
KOLLE RAMESH
S/o K BHASKAR RAO
R/o MM DIST
For Whom
** SELF **

S SREELAXMI
LICENSED STAMP VENDOR
Lic. No. 15-21-11/2017
Ren.No. 15-21-044/2023
FLAT NO. G1, KANCHANA
RESIDENCY, KAKATIYA
NAGAR, CHINTAL,
QUTHBULLAPUR MANDAL,
MEDCHAL MALKAJGIRI
DISTRICT, TELANGANA
STATE
Ph 7780692454

Ref.: Confirmation of receipt of Compensation

Ref: Demise of Mr. B. Anil Kumar (Aadhar No.860953056959) S/o. Ananthagiri, in your manufacturing Plant on 20th November, 2024 at 10.20 am on account of flash fire to leading accidental death.

I, B. Sunitha, W/o. Anil Kumar (Aadhar No.836240835883), hereby confirm the receipt of Rs.42 Lakhs (Rupees Forty Two Lakhs) towards full and complete compensation against the demise of my husband B. Anil Kumar (Aadhar No.860953056959) S/o. Ananthagiri, caused on account of flash fire to leading to accidental death.

I further confirm that myself, my children, my husband's parents or any other person will not claim any other or any further compensation on account of this loss either from you or from Aurore Pharmaceuticals private limited.

B. Sunitha

34

:: 2 ::

Acknowledge receipt of cheques as detailed below :-

Cheq.No	Date	Bank	Amount (Rs)
730082	25.11.2024	Yes Bank	10,00,000/- (Rs. Ten Lakhs)
730083	07.12.2024	Yes Bank	10,00,000/- (Rs. Ten Lakhs)
730087	27.12.2024	Yes Bank	10,00,000/- (Rs. Ten Lakhs)
730085	06.01.2025	Yes Bank	11,00,000/- (Rs. Eleven akhs)

In addition to the above received in cash Rs.100,000/- (Rupees One Lakh only) for cremation and performing final rites of the departed soul.

Yours faithfully,

B. Sunitha

B. Sunitha

(Aadhar No.836240835883)

W/o. Late B. Anil Kumar (Aadhar No.860953056959)

Witness:

1.

2.

20th November 2024

Venugopal Reddy Gudise (Proprietor),
Venkateswara Enterprises,
H.No..33-84, New Shapur Nagar, IDA,
feedimetla, Hyderabad - 500055.

Dear Sir,

Re: Confirmation of receipt of Compensation

Ref: Demise of Mr. B Anil Kumar (Aadhar No: 860953056959) S/o. Ananthagiri, in your manufacturing plant on 20th November 2024 at 10.20 am on account of flash fire to leading to accidental death.

I B Sunitha, w/o Anil Kumar (Aadhar No:836240835883), hereby confirm receipt of Rs. 42 Lakhs (Rupees Forty two lakhs), towards full and complete compensation against the demise of my husband B Anil Kumar (Aadhar No: 860953056959) S/o. Ananthagiri, caused on account of flash fire to leading to accidental death.

I further confirm that myself, my children, my husband's parents or any other person will not claim any other or any further compensation on account of this loss either from you or from Aurore Pharmaceuticals private limited.

Acknowledge receipt of cheques as detailed below:

Cheq.No	Date	Bank	Amount (Rs)
730082	25.11.2024	Yes Bank	10,00,000/- (Rs Ten Lakhs)
730083	07.12.2024	Yes Bank	10,00,000/- (Rs Ten Lakhs)
730084	27.12.2024	Yes Bank	10,00,000/- (Rs. Ten Lakhs)
730085	06.01.2025	Yes Bank	11,00,000/- (Rs. Eleven Lakhs)

In addition to the above received in cash Rs.100,000/- (Rupees One Lakh only) for cremation and performing final rites of the departed soul.

Yours faithfully,

B Sunitha

B Sunitha,

(Aadhar No: 836240835883)

W/o Late B Anil Kumar (Aadhar No: 860953056959)

R. Praveen Yadav
9866382794
G. Jayaram
7396644222
G. Jayaram

3. G. V. Ravey
9010404028

YES Prosperity

YES BANK Ltd., GROUND FLOOR, PRESTIGE OBELISK MUNICIPAL NO 3
KASTURBA ROAD BANGALORE 560001
IFS CODE: YES0000022

Valid for 3 months only

Date 25/11/2024

Pay B. Sunitha

Or Bearer
या धारक को

Amount रु Ten Lakhs Only

अंश करें

₹ 10,00,000/-

CURRENT

A/C NO.
002281400004997

For AURORE PHARMACEUTICALS PVT LTD



[Handwritten Signature]
Authorised Signatories
Please sign above

Payable at par through clearing/transfer at all branches of YES BANK

IF 73008 21 56053 200 20 04924 21 29

B Sunitha

36

YES Prosperity

YES BANK Ltd., GROUND FLOOR, PRESTIGE OBELISK MUNICIPAL NO 3
102 STURDA ROAD BANGALORE 560001
IFS CODE : YESB0000022

Valid for 3 months only

Date 07/12/2024

Pay B. Sunita

Dr Beant
या धारक व

Payable to Ten Lakhs Only

अदा करें

₹ 10,00,000/-

CURRENT

ACC NO.
BRANCH

002281400004997

For AURORE PHARMACEUTICALS PVT LTD

YES BANK

[Handwritten Signature]

Authorised Signatories
Please sign above

Payable at par through clearing/transfer at all branches of YES BANK

⑈ 730083⑈ 560532002⑈ 049242⑈ 29

B. Sunita

37

YES Prosperity

YES BANK Ltd., GROUND FLOOR, PRESTIGE OBELISK MUNICIPAL NO 3
KASTURBA ROAD BANGALORE 560001
IFS CODE : YES0000022

Valid for 3 months only

Date 27/12/2024

Pay to the order of B. Sunitha

Or Bearer
या धारक को

Amount in words Ten Lakhs Only

अदा करें

₹ 10,00,000/-

CURRENT

PNIC NO. 002261400004997

For AURORE PHARMACEUTICALS PVT LTD



[Handwritten Signature]

Authorised Signatories
Please sign above

Payable at par through clearing/transfer at all branches of YES BANK

⑈ 730084⑈ 56053 200 2⑈ 049242⑈ 29

B. Sunitha

38

YES Prosperity

YES BANK Ltd., GROUND FLOOR, PRESTIGE OBELISK MUNICIPAL NO 3
KASTURBA ROAD BANGALORE 560001
IFS CODE : YES0000022

Valid for 3 months only

Date 06 01 20 25

Pay B. Sunitha

Or Bearer

या धारक को

अनुमति केवल लकीरें के लिए

अदा करें

₹ 11,00,000/-

CURRENT

A/C NO.
एक अंक

002281400004997

For AURORE PHARMACEUTICALS PVT LTD

✓ YES BANK

Authorised Signatories

Please sign above

Payable at par through clearing/transfer at all branches of YES BANK

IF 73008 5IF 56053 200 2IF 04924 2IF 29

B. Sunitha

39

40



తెలంగాణ తెలంగాణ TELANGANA

S. Sree Caremi
BG 419776

Tran Id: 241120200718389366
Date: 20 NOV 2024, 08:11 PM
Purchased By:
KOLLE RAMESH
S/o K BHASKAR RAO
R/o MM DIST
For Whom
** SELF **

S SREELAXMI
LICENSED STAMP VENDOR
Lic. No. 15-21-11/2017
Ren.No. 15-21-044/2023
FLAT NO. G1, KANCHANA
RESIDENCY, KAKATTYA
NAGAR, CHINTAL,
QUTHBULLAPUR MANDAL,
MEDCHAL MALKAJGIRI
DISTRICT, TELANGANA
STATE
Ph 7780692454

Ref.: Confirmation of receipt of Compensation

Ref: Demise of Mr. Balaram Majji (Aadhar No.462899639772) S/o. Majji Tirupathi Naidu, in your manufacturing Plant on 20th November, 2024 at 10.20 am on account of flash fire to leading accidental death on 23rd November, 2024

I, Sri Devi Majji, W/o. Balaram (Aadhar No:674755223605), hereby confirm the receipt of Rs.45 Lakhs (Rupees Forty Five Lakhs) towards full and complete compensation against the demise of my husband Balaram Majji (Aadhar No: 462899639772) S/o. Majji Tirupathi Naidu, caused on account of flash fire to leading to accidental death.

I further confirm that myself, my children, my husband's parents or any other person will not claim any other or any further compensation on account of this loss either from you or from Aurore Pharmaceuticals private limited.

M. S. Sree

(41)

:: 2 ::

Acknowledge receipt of cheques as detailed below :

Cheq.No	Date	Bank	Amount (Rs)
730088	28.11.2024	Yes Bank	10,00,000/- (Rs. Ten Lakhs)
730089	10.12.2024	Yes Bank	10,00,000/- (Rs. Ten Lakhs)
730090	25.12.2024	Yes Bank	10,00,000/- (Rs. Ten Lakhs)
730091	12.01.2025	Yes Bank	10,00,000/- (Rs. Ten Lakhs)
730092	20.01.2025	Yes Bank	5,00,000/- (Rs. Five Lakhs)

In addition to the above received in cash Rs.100,000/- (Rupees One Lakh only) for cremation and performing final rites of the departed soul.

Yours faithfully,

M. श्रीदेवी

Sri Devi Majji

(Aadhar No. 674755223605)

W/o. Late Balaram Majji (Aadhar No.432899639772)

Witness:

(1.) B. Hema Sander Rao.
(2.) Rajesh

(3.) [Signature]
(4.) K. Subhaji

YES Prosperity

YES BANK Ltd., GROUND FLOOR, PRESTIGE UBEL SK MUNICIPAL NO 3
KASTURBA ROAD BANGALORE 560006
JFS CODE : YESB0000022

Payee

.Valid for 3 months only

Date 28/11/2024

SRI DEVI MAJJI

Or Bearer
या धारक को

TEN LAKH ONLY

अव करें

₹ 10,00,000/-

CURRENT

002281400004997

For AURORE PHARMACEUTICALS PVT LTD



Payment through clearing/transfer at all branches of YES BANK

Authorised Signatories
Please sign above

730088 56053200 049242 29

42

1. M. श्रीदेवी
2. Rajesh
3. B. Hemant Kumar

YES Prosperity
Business

YES BANK Ltd., GROUND FLOOR, PSEFOTIPE APPLSK MUNICIPAL NO 3
KASTURBA ROAD BANGALORE
IFS CODE : YES00000022

Valid for 3 months only

Date 10/12/2024

UTILITY FORMS PVT. LTD. / CTB - 2010

Pay **SRI DEVI MAJJI**

Or Bearer
या धारक को

Rupees **रुपये TEN LAKH ONLY**

₹ 10,00,000/-

अदा करें

CURRENT

A/C NO.
खाता क्र. **002281400004997**

For AURORE PHARMACEUTICALS PVT LTD



YES BANK

Authorised Signatories
Please sign above

Payable at par through clearing/transfer at all branches of YES BANK

730089 560532002 049242 29

M. राजेश
Rajesh

B. Hemasendra Rao

(103)

YES Prosperity

YES BANK Ltd., GROUND FLOOR, PRESTIGE UBESK MUNICIPAL NO 3
KASTURBA ROAD BANGALORE 560006
IFS CODE : YESB0000022

Valid for 3 months only

Date 11 20 11 26 25

SRI DEVI MAJJI

Or Bearer
या धारक को

TEN LAKH ONLY

अथवा करें

₹ 10,00,000/-

CURRENT

AN NO
BANK OF

602281400004997

✓ YES BANK

Payments at net through clearing/transfer at all branches of YES BANK

For AURORE PHARMACEUTICALS PVT LTD

Authorised Signatories
Please sign above

73009 56053 200 04924 29

M. श्रीदेवी

Rajesh

B. Hema Sundarao

45

YES Prosperity

YES BANK Ltd., GROUND FLOOR, PLEASANT CHURCH MUNICIPAL NO 3
KASTURBA ROAD BANGALORE 560001
IFS CODE : YESB0000022

Valid for 3 months only

Date 20 01 20 25

SRI DEVI MAJJI

Or Bearer
या धारक को

FIVE LAKH ONLY

अदा करें

₹ 5,00,000/-

CHARIT

002281400004997

For AURORE PHARMACEUTICALS PVT LTD



Payable at all branches of YES BANK

Authorised Signatories
Please sign above

⑈ 73009 2⑈ 56053 200 2⑈ 049 24 2⑈ 29

M. S. Rajesh

Rajesh

B. Hema Sunda Rao

947

Item No.02:-

BEFORE THE NATIONAL GREEN TRIBUNAL
SOUTHERN ZONE, CHENNAI

[Through Physical Hearing (Hybrid Option)]

Original Application No.20 of 2025(SZ)

[Earlier O.A. No. 1341 of 2024(PB)]

IN THE MATTER OF:

Tribunal on its own motion Suo Moto based on the news item in The Times of India dated 21.11.2024 titled "One dead 3 injured in reactor blast at pharma company in Hyderabad".

And

Telangana State Pollution Control Board,
Through its Member Secretary,
Telangana and Ors.



...Respondent(s)

Date of hearing: 08.02.2025.

CORAM:

HON'BLE Smt. JUSTICE PUSHPA SATHYANARAYANA, JUDICIAL MEMBER

HON'BLE Dr. SATYAGOPAL KORLAPATI, EXPERT MEMBER

For Applicant(s):	Suo Motu.
For Respondent(s):	M/s. Nathami for R2. Ms. Niveditha represented Mrs. H. Yasmeen Ali for R4.

ORDER

1. The above case has been Suo Motu registered by the Principal Bench of the National Green Tribunal, New Delhi as Original Application No.1341 of 2024 (PB) based on the news item published in 'The Times of India' dated 21.11.2024 titled "**One dead 3 injured in reactor blast at pharma company in Hyderabad**", which has been transferred to this Bench and renumbered as Original Application No.20 of 2025 (SZ).

2. Let the notices be issued to the respondents through the Tribunal.

3. The learned counsel Mrs. Nathami accepts notice on behalf of the 2nd Respondent and Ms. Niveditha representing Mrs. H. Yasmeen Ali accepts notice on behalf of the 4th Respondent.

4. Post the matter on **01.04.2025**. Meanwhile, the respondent authorities are directed to file their respective reports/replies.

Sd/-

Smt. Justice Pushpa Sathyanarayana, JM

Sd/-

Dr. Satyagopal Korlapati, EM

O.A. No.20/2025(SZ)
08th February, 2025. Mn.